A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function

J Immunol. 2014 Nov 1;193(9):4439-47. doi: 10.4049/jimmunol.1303077. Epub 2014 Sep 26.

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the CNS, and autoreactive CD4(+) T cells are considered important for its pathogenesis. The etiology of MS involves a complex genetic trait and environmental triggers that include viral infections, particularly the EBV. Among the risk alleles that have repeatedly been identified by genome-wide association studies, three are located near the Casitas B-lineage lymphoma proto-oncogene b gene (CBLB). The CBLB protein (CBL-B) is a key regulator of peripheral immune tolerance by limiting T cell activation and expansion and hence T cell-mediated autoimmunity through its ubiquitin E3-ligase activity. In this study, we show that CBL-B expression is reduced in CD4(+) T cells from relapsing-remitting MS (RR-MS) patients during relapse. The MS risk-related single nucleotide polymorphism of CBLB rs12487066 is associated with diminished CBL-B expression levels and alters the effects of type I IFNs on human CD4(+) T cell proliferation. Mechanistically, the CBLB rs12487066 risk allele mediates increased binding of the transcription factor C/EBPβ and reduced CBL-B expression in human CD4(+) T cells. Our data suggest a role of the CBLB rs12487066 variant in the interactions of a genetic risk factor and IFN function during viral infections in MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics*
  • Alleles
  • CCAAT-Enhancer-Binding Protein-beta / metabolism
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Gene Expression Regulation
  • Genetic Predisposition to Disease*
  • Genetic Variation*
  • Genotype
  • Humans
  • Interferon Type I / metabolism
  • Interferon Type I / pharmacology
  • Interferon Type I / therapeutic use
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / metabolism
  • Phenotype
  • Polymorphism, Single Nucleotide
  • Protein Binding
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-cbl / genetics*
  • Treatment Outcome

Substances

  • Adaptor Proteins, Signal Transducing
  • CCAAT-Enhancer-Binding Protein-beta
  • Interferon Type I
  • MAS1 protein, human
  • Proto-Oncogene Mas
  • CBLB protein, human
  • Proto-Oncogene Proteins c-cbl